No other way to explain it other than CRIMINAL!
ROSG`s brokers are the worst i`ve seen in 30 years!! Where`s Bernie at? Wall Street and the Investment Banks need a heavy dose of regulation to right the ship.
These brokers are crooks IMO!
Regulators have given one of the world's largest drug companies approval to sell a new gene therapy.
The treatment is for an illness called ADA-SCID which prevents babies from fighting off everyday infections.
This is the first approval for a genetic therapy granted to a large multinational drug company, GSK.
Commentators say the development marks the beginning of many more genetic medicines from so-called "Big Pharma".
The condition is extremely rare and affects around two dozen babies each year.
Approval of the gene therapy paves the way for the development of treatments for more widespread illnesses such as thalassemia and sickle cell disease.
Hundreds of inherited disorders such as cystic fibrosis, muscular dystrophy and many types of blindness are caused by faulty genes.
The aim of gene therapies is to cure the disease by introducing healthy copies of the gene into the patient.
And the big advantage of the treatment is that it only needs to be given once and it offers a potentially permanent cure.
The idea first emerged with much hype 30 years ago. At the time, large drug companies such as Novartis and Roche were at the forefront of the technology.
Advocates of gene therapy said it would cure everything but, for 20 years, it cured nothing.
The practicalities of introducing the right gene in the right cells and getting them to stick proved more difficult than first thought.
There were huge setbacks for the technology in the early days.
In 1999, an 18-year-old man Jesse Gelsinger died in a clinical trial of a gene therapy to treat a liver disease. The virus used to transfer the gene into his cells triggered his immune system into overdrive which led to multiple organ failure and brain death.
Three years later, children being treated in Paris for a problem with their immune system developed leukaemia because the healthy gene was inserted too close to a cancer-causing gene which consequently became active.
The setbacks saw large drug companies withdraw from research in the field.
Small biotechnology companies and publicly funded research groups persevered and, in time, many of the early difficulties were overcome.
As well as today's approval of GSK's treatment, which the company calls Strimvelis, in 2012 regulators gave the green light to a gene therapy called Glybera for a pancreatic disorder and another last year called T-Vec for skin cancer.
According to Prof Alan Boyd, who is president of the Faculty of Pharmaceutical Medicine and a pioneer in the development of gene therapy, more approvals are likely to be given in the next few years.
"Most of the hard work has been done by small companies. But as some of these products have come closer to market, Big Pharma has come back in," he says.
GSK's Strimvelis marks a starting point for the company to develop its gene therapies. It has research programmes under way for three relatively rare diseases and a programme and another collaboration to use gene therapy to treat cancers.
One of the issues for Big Pharma is how can it make money out of gene therapy. If one treatment cures its customers then is the industry not in danger of putting itself out of business?
GSK's position and those of other drug companies is that it can't afford not to become involved in gene therapy.
If the vision to treat people with one-off treatments that last a long time becomes a reality, any part of the industry that chooses to ignore gene therapy will be in an awful lot of trouble.
So the time is now right for large drug companies companies to become involved in gene therapy again. The question for Big Pharma the how much to charge for a single life-long cure?
Accessible to patients
GSK has not released details of how it will price its new treatment yet but its president of R&D, Patrick Vallance, says that the aim would be to make Strimvelis and any more gene therapies it develops as accessible as possible to as many patients as it can.
"We are absolutely committed to getting the price right," he says. "It's obvious that you can't charge a price that is unaffordable."
No doubt the pricing will work itself out in the long run and as more trials come through, the cost of gene therapy treatments will get less and less.
I would rather not sale and get $100.00 share.
The spread of Zika is the price being paid for a massive policy failure on mosquito control, says World Health Organization leader Margaret Chan.
Speaking at the agency's annual World Health Assembly, Dr Chan said experts had "dropped the ball" in the 1970s with regards to getting a handle on disease-carrying insects.
More than 60 countries and territories now have continuing Zika transmission.
Most recently, the infection, spread by mosquito bites, reached Africa.
At the current PPS i am adding every chance i get and will not sale a single share. Crazy manipulation with this stock. Longs will reap handsome rewards, just hang in there and keep adding!
Especially those spewing lies.
Nearly 300 pregnant women in US test positive for Zika
2 hours ago
From the section US & Canada
The Zika virus is especially dangerous for pregnant women
Zika outbreak: What you need to know
Zika outbreak: Travel advice
Mothers' fears amid Zika outbreak
Video How mums-to-be are tackling Zika
Nearly 300 pregnant women in the US have tested positive for Zika virus, according to the latest figures from the Centers for Disease Control and Prevention (CDC).
In the US, 157 pregnant women have tested positive for the disease and 122 have tested positive in US territories.
Until now, the agency had not reported the number of women infected by the diseases in the US and its territories.
A Zika-related has been reported in the French Caribbean Island of Martinique.
A regional health agency said on Friday an 84-year-old patient with Guillain Barre Syndrome who had been in the hospital for ten days died.
Some experts think there is a link between the syndrome and Zika virus.
The virus is spread through mosquitoes and sexual contact.
It can cause microcephaly, a birth defect, marked by a small head size and can lead to developmental problems in infants.
Symptoms of Zika virus include mild fever, conjunctivitis, headache, joint pain and rashes.
More on the Zika crisis:
Map showing the countries that have had confirmed cases of the Zika virus
Microcephaly: Why it is not the end of the world
What you need to know Key questions answered about the virus and its spread
Travel advice Countries affected and what you should do
The mosquito behind spread of virus What we know about the insect
Abortion dilemma Laws and practices in Catholic Latin America
Death from the disease is rare and there is no vaccine or drug treatment available.
In Los Angeles, officials are taking prevention measures against Zika after health officials warned that outbreaks could be expected in Southern California.
The outbreak began nearly a year ago in Brazil.
The World Health Organization has said Zika virus could spread to Europe this summer.
"Everything we know about this virus seems to be scarier than we initially thought," Dr Anne Schuchat of the CDC said in April.
Earlier this year, US President Barack Obama asked the US Congress for $1.9bn (£1.25bn) in emergency funding to combat the virus.
In the meantime it has been using money totalling $589m left over from the Ebola virus fund.
The Zika virus strain responsible for the outbreaks in Brazil has been detected in Africa for the first time, the World Health Organization says. Just found this on BBC News.
Maybe he has a life to live and could use some cash.
Yeah but, the way their revenue is increasing big time from quarter to quarter .They may not need to burn thru their cash.